Skip to main content

Table 4 EORTC QLQ-H&N35 scoring at the onset and end of assessment in 17 H&N PGL patients

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Variables

Baseline QLQ

Post-therapy QLQ

P value

Pain

51.8 ± 22.7

26.8 ± 20.8

0.001

Swallowing

31.4 ± 33.3

17.31 ± 16.6

0.001

Senses (taste and smell)

11.1 ± 24.9

10.1 ± 24.3

0.903

Speech

34.5 ± 22.2

30.2 ± 22.2

0.296

Social eating

31.1 ± 33.3

16.6 ± 16.6

0.002

Social contact

29.6 ± 23.7

19.6 ± 19.5

0.074

Sexuality

28.7 ± 25

31.4 ± 16.6

0.562

Teeth

25.9 ± 33.3

16.6 ± 0.1

0.244

Opening mouth

44.4 ± 50

24 ± 33.3

0.158

Dry mouth

18.5 ± 33.3

11.1 ± 0.1

0.125

Sticky saliva

11.1 ± 16

3.7 ± 10.7

0.112

Coughing

38.8 ± 33.3

20.3 ± 16.6

0.042

Felt ill

48.1 ± 26.1

27.7 ± 32.8

0.046

Painkiller

83.3 ± 38.3

18.5 ± 17

0.000

Nutritional supplement

44.4 ± 51.5

18.6 ± 12.7

0.046